Skip to content
value.today

China Medicine Corp.

Formerly Lounsberry Holdings III, Inc.

Total raised
$70 M
1 round on record
Latest round
$70 M
Jan 2010
First round on record
Jan 2010
Today
Private
No later event on record

Funding rounds

1 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of China Medicine Corp.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jan 2010$70 MNo. 1$50 to $250 million

China Medicine Corp.: Raise no. 1, Jan 2010

Investors in this round

1 investor had bought by the notice of Jun 9, 2010: 0 accredited, 1 not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$70 M of $70 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
$25 million to $100 million
Sales commissions
none
Finders' fees
$2,088,000
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Nevada

People named in the notice

  • Fred Cheung · Executive Officer · Chief Financial Officer
  • Minhua Liu · Director, Executive Officer · Executive Vice President
  • Senshan Yang · Director, Executive Officer · Chief Executive Officer
  • Daniel Shih · Director
  • Ian Grant Robinson · Director
  • Rachel Gong · Director
  • Ryan Shih · Director
  • Sean Shao · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Peak Capital Advisory Limited · Central, Hong KongSold in no state named

Remarks in the notice

  • On fees: “As part of the expenses of the offering, Peak received a cash fee. It is also entitled to an equity fee of 232,000 shares. Issuer may be obliged to issue up to an additional 464,000 shares to Peak under certain circumstances.”
  • On the amounts: “Sale of 4,000,000 shares of common stock, par value $0.0001 per share, at $3.00 per share; and 1,920,000 shares of redeemable convertible preferred stock, par value $0.0001 per share, at $30.00 per share.”

Signed by Senshan Yang, Chief Executive Officer. Newest notice filed Jun 9, 2010 (1 amendment). Read the notice at the SEC.

equitySEC

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • China Medicine Corp. had revenue between $25 million and $100 million when it filed its newest notice of a funding round (Jun 2010).

    SEC Form D (revenue range) · Jun 2010

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Jun 2010

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of China Medicine Corp. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by China Medicine Corp.
NameRoleNamed in
Fred CheungChief Financial OfficerJun 2010
Minhua LiuExecutive Vice PresidentJun 2010
Senshan YangChief Executive OfficerJun 2010
Robert LuExecutive officerMay 2010
Daniel ShihDirectorJun 2010
Ian Grant RobinsonDirectorJun 2010
Minhua LiuExecutive Vice PresidentJun 2010
Rachel GongDirectorJun 2010
Ryan ShihDirectorJun 2010
Sean ShaoDirectorJun 2010
Senshan YangChief Executive OfficerJun 2010
Robert AdlerDirectorMay 2010
Yangfang ChenDirectorMay 2010